Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment.

Ekmekciu I, von Klitzing E, Fiebiger U, Neumann C, Bacher P, Scheffold A, Bereswill S, Heimesaat MM.

Front Cell Infect Microbiol. 2017 May 5;7:167. doi: 10.3389/fcimb.2017.00167. eCollection 2017.

2.

Potential role of nutraceutical compounds in inflammatory bowel disease.

Larussa T, Imeneo M, Luzza F.

World J Gastroenterol. 2017 Apr 14;23(14):2483-2492. doi: 10.3748/wjg.v23.i14.2483. Review.

3.

Clinical Evidence for the Microbiome in Inflammatory Diseases.

Slingerland AE, Schwabkey Z, Wiesnoski DH, Jenq RR.

Front Immunol. 2017 Apr 12;8:400. doi: 10.3389/fimmu.2017.00400. eCollection 2017. Review.

4.

The Role of Probiotics in IBD.

Katz J.

Gastroenterol Hepatol (N Y). 2006 Jan;2(1):16-18. No abstract available.

5.

The enteric nervous system promotes intestinal health by constraining microbiota composition.

Rolig AS, Mittge EK, Ganz J, Troll JV, Melancon E, Wiles TJ, Alligood K, Stephens WZ, Eisen JS, Guillemin K.

PLoS Biol. 2017 Feb 16;15(2):e2000689. doi: 10.1371/journal.pbio.2000689. eCollection 2017 Feb.

6.

Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases.

Shigemori S, Shimosato T.

Front Immunol. 2017 Jan 25;8:22. doi: 10.3389/fimmu.2017.00022. eCollection 2017. Review.

7.

Recent advances in understanding and managing Crohn's disease.

Stange EF, Wehkamp J.

F1000Res. 2016 Dec 21;5:2896. doi: 10.12688/f1000research.9890.1. eCollection 2016. Review.

8.

Cross feeding of glucose metabolism byproducts of Escherichia coli human gut isolates and probiotic strains affect survival of Vibrio cholerae.

Sengupta C, Ekka M, Arora S, Dhaware PD, Chowdhury R, Raychaudhuri S.

Gut Pathog. 2017 Jan 17;9:3. doi: 10.1186/s13099-016-0153-x. eCollection 2017.

9.

Involvement of Reduced Microbial Diversity in Inflammatory Bowel Disease.

Gong D, Gong X, Wang L, Yu X, Dong Q.

Gastroenterol Res Pract. 2016;2016:6951091. doi: 10.1155/2016/6951091. Epub 2016 Dec 15. Review.

10.
11.

Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Hudson LE, Anderson SE, Corbett AH, Lamb TJ.

Clin Microbiol Rev. 2017 Jan;30(1):191-231. Review.

PMID:
27856521
12.

Insights from 100 Years of Research with Probiotic E. Coli.

Wassenaar TM.

Eur J Microbiol Immunol (Bp). 2016 Sep 29;6(3):147-161. eCollection 2016 Sep 29. Review.

13.

New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases.

Vieira AT, Fukumori C, Ferreira CM.

Clin Transl Immunology. 2016 Jun 24;5(6):e87. eCollection 2016 Jun. Review.

14.

Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Currò D, Ianiro G, Pecere S, Bibbò S, Cammarota G.

Br J Pharmacol. 2017 Jun;174(11):1426-1449. doi: 10.1111/bph.13632. Epub 2016 Oct 25. Review.

PMID:
27696378
15.

Extraintestinal pathogenic Escherichia coli are associated with intestinal inflammation in patients with ulcerative colitis.

Mirsepasi-Lauridsen HC, Halkjaer SI, Mortensen EM, Lydolph MC, Nordgaard-Lassen I, Krogfelt KA, Petersen AM.

Sci Rep. 2016 Sep 30;6:31152. doi: 10.1038/srep31152.

16.

Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.

Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M.

World J Gastroenterol. 2016 Aug 28;22(32):7186-202. doi: 10.3748/wjg.v22.i32.7186. Review.

17.

Outer Membrane Vesicles from the Probiotic Escherichia coli Nissle 1917 and the Commensal ECOR12 Enter Intestinal Epithelial Cells via Clathrin-Dependent Endocytosis and Elicit Differential Effects on DNA Damage.

Cañas MA, Giménez R, Fábrega MJ, Toloza L, Baldomà L, Badia J.

PLoS One. 2016 Aug 3;11(8):e0160374. doi: 10.1371/journal.pone.0160374. eCollection 2016.

18.

The hygiene hypothesis: current perspectives and future therapies.

Stiemsma LT, Reynolds LA, Turvey SE, Finlay BB.

Immunotargets Ther. 2015 Jul 27;4:143-57. doi: 10.2147/ITT.S61528. eCollection 2015. Review.

19.

Enterococcus durans TN-3 Induces Regulatory T Cells and Suppresses the Development of Dextran Sulfate Sodium (DSS)-Induced Experimental Colitis.

Kanda T, Nishida A, Ohno M, Imaeda H, Shimada T, Inatomi O, Bamba S, Sugimoto M, Andoh A.

PLoS One. 2016 Jul 20;11(7):e0159705. doi: 10.1371/journal.pone.0159705. eCollection 2016.

20.

Synergic Interaction of Rifaximin and Mutaflor (Escherichia coli Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats.

Dembiński A, Warzecha Z, Ceranowicz P, Dembiński M, Cieszkowski J, Gosiewski T, Bulanda M, Kuśnierz-Cabala B, Gałązka K, Konturek PC.

Gastroenterol Res Pract. 2016;2016:3126280. doi: 10.1155/2016/3126280. Epub 2016 Jun 28.

Supplemental Content

Support Center